Literature DB >> 9743295

P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma.

S D Shnyder1, A J Hayes, J Pringle, C W Archer.   

Abstract

The expression of the drug resistance (DR) mediators P-glycoprotein (P-gp) and the metallothioneins (MT) was assessed immunohistochemically in biopsy material from patients with high-grade malignant osteosarcoma (OS). No significant difference was found in survival rate between expressors of both P-gp and MT and non-expressors. Thus, it was concluded that lack of expression of these two drug resistance-related proteins does not appear to confer any advantage in terms of patient survival in osteosarcoma.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9743295      PMCID： PMC2062957          DOI： 10.1038/bjc.1998.573

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  10 in total

Review 1.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

Authors:  P A Andrews; S B Howell
Journal:  Cancer Cells       Date:  1990-02

2.  Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule.

Authors:  P van der Valk; C K van Kalken; H Ketelaars; H J Broxterman; G Scheffer; C M Kuiper; T Tsuruo; J Lankelma; C J Meijer; H M Pinedo
Journal:  Ann Oncol       Date:  1990       Impact factor: 32.976

3.  Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.

Authors:  K Kasahara; Y Fujiwara; K Nishio; T Ohmori; Y Sugimoto; K Komiya; T Matsuda; N Saijo
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

4.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

Authors:  R L Juliano; V Ling
Journal:  Biochim Biophys Acta       Date:  1976-11-11

5.  Mammalian metallothionein is functional in yeast.

Authors:  D J Thiele; M J Walling; D H Hamer
Journal:  Science       Date:  1986-02-21       Impact factor: 47.728

6.  Metallothionein in testicular germ cell tumors and drug resistance. Clinical correlation.

Authors:  J L Chin; D Banerjee; S A Kadhim; T E Kontozoglou; P J Chauvin; M G Cherian
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

7.  Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder.

Authors:  R R Bahnson; B F Banner; M S Ernstoff; J S Lazo; M G Cherian; D Banerjee; J L Chin
Journal:  J Urol       Date:  1991-12       Impact factor: 7.450

8.  Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines.

Authors:  Y Kondo; S M Kuo; S C Watkins; J S Lazo
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

9.  Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.

Authors:  V M Richon; N Schulte; A Eastman
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

10.  Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study.

Authors:  R A Kandel; S Campbell; S Noble-Topham; R Bell; I L Andrulis
Journal:  Diagn Mol Pathol       Date:  1995-03
  10 in total
  6 in total

1.  Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.

Authors:  Eisuke Kobayashi; Arun K Iyer; Francis J Hornicek; Mansoor M Amiji; Zhenfeng Duan
Journal:  Clin Orthop Relat Res       Date:  2013-03       Impact factor: 4.176

2.  Metallothionein expression in hepatocellular carcinoma.

Authors:  Geng-Wen Huang; Lian-Yue Yang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

3.  Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.

Authors:  L Endo-Munoz; A Cumming; S Sommerville; I Dickinson; N A Saunders
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

4.  Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi.

Authors:  Célia M F Gomes; Mick Welling; Ivo Que; Niek V Henriquez; Gabri van der Pluijm; Salvatore Romeo; Antero J Abrunhosa; M Filomena Botelho; Pancras C W Hogendoorn; Ernest K J Pauwels; Anne Marie Cleton-Jansen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-01       Impact factor: 9.236

5.  Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance.

Authors:  N Habel; Z Hamidouche; I Girault; A Patiño-García; F Lecanda; P J Marie; O Fromigué
Journal:  Cell Death Dis       Date:  2013-10-24       Impact factor: 8.469

6.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.